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GRAFT VERSUS HOST DISEASE (GVHD)
Immuno genet i c s
Goulmy has reported during the previous meeting the occurrence of cyto-
toxic lymphocytes (CTL's) in a patient suffering from chronic GVHD
after allogeneic bone marrow transplantation for acute myeloid leukae-
thus the recognition of genetic differences between HLA-identical sib-
lings, for instance the CTL's reacted with the patient's own pretrans-
plant lymphocytes, but not with the
against a non-HLA determinant (HA)
ntigens of the donor. They allow
donor's lymphocytes. Similar CTL's
have been described by Elkens et al. in a patient, who had become sen-
sitized after multiple blood transfusions (3).
Goulmy et al. suggested that the antji-HA CTL's could and should be
used to study their relevance in the! occurrence of GVHD. In a collabo-
rative effort with the bone marrow tjransplant group of the l'Hopital
St. Louis, in Paris (Head: Prof. _E_. iGluckman) and_of the University
Hospital Leiden (Head: Prof.Dr. J.J.j Veitkamp) preliminary evidence has
been collected which indicate that i(ncompatibility for HA (or other non-
HLA CTJU determinants) can lead to GVHD.
Table I. Relation between mismatchesi Table II. CML reactivity be-
for non-HLA determinants between donior tween HLA-identical donor-
and recipient and GVHD (Leiden-Paris;)
non-HLA mismatches
recipient combinations (Leiden-
Paris)
chron. acute
Acute GVHD
Chronic GVHD
not
detected
19
2
HA
0
3
otherj
0
4 >
CML pos,
neg.
GVHD
6
2
GVHD
ρ = 0.02
Table I shows that in chronic GVHD but not in acute GVHD differences
for HA (or its allele) could be found. Likewise a positive CML was
found between post- and pretransplant lymphocytes from patients suffer-
jing from chronic GVHD but not from such patients suffering from acute
'GVHD (Table II). Our preliminary conclusion is that such CTL's can re-
cognize non-HLA but MHC restricted determinants and that incompatibi-
jlity for these determinants could lejad to GVHD.
. /Ρι_ Κ! Ί
ι II
2.
,Immune modulation
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|We have discussed in previous reports the possibility that the finding
that pretransplant blood transfusiom can facilitate renal allograft
(survival might also be relevant in bone marrow transplantation. Recent-
!ly it has been shown that in primates and mice not only whole blood but
lalso pure platelets can induce this so-called pretransplant blood trans
fusion effect (4,5). In mice it was\shown that heat pretreated leuco-
cytes behaved as platelets as far as the graft protecting effect was
concerned. On the basis of these fimdings it was investigated in a
mouse model whether platelets obtaiAed from the future recipient and
given to the bone marrow donor would mitigate GVHD. Figure 1 shows that
this is indeed the case. Note that if the donor receives recipient's
leucocytes GVHD is more severe, while survival is improved (and GVHD is
lessened) if pure platelets are given.
l
I
Figure 1. Survival· of (B10.T(6R) χ &1O.A(2R))F1 mice following a bone
marrow transplantation wilh B10.AQR spieen cells. Donor pre-
treatment: • = pretreated with recipient leucocytes; · = not
pretreated; + = pretreatm^nt with heat-treated leucocytes of
the recipient. (Claas et al. 1982)
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Of course these data cannot be extra;polatcd to man without extensive
preclinical testing (dogs, monkeys). Even if such experiments would
corroborate the findings in the mousie, ethical considerations would
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jprobably exclude their application in the clinical Situation. However
if we would understand the mechanisia of the pretransplant blood trans-
fusion effect we might be able to "tireat" the bone marrow in vitro and
induce in that manner the "blood transfusion effect" without harming
the bone marrow donor.
I
|THE UNRELATED DONOR
ι
IHaploidentical bone marrow donors (3-g. the parents) seem to give good
results especially in younger Ieuka4mic patients. For older especially
aplastic anaemia patients unrelated Jwell matched donors seem at the
moment the best choice. Very littleiis known how "well matched" should
be interpreted. Is complete identity necessary or can partially mis-
matched bone marrow be used as well? Especially relevant in this respec
are the experiments by Wagemaker et al. who could show that stem cell
preparation infused in decontaminated monkeys would not lead to GVHD if
donor and recipient were matched for class I antigens, while matching
for class II antigens seemed to be less important (6).
Termijtelen et al. has described the difficulties of finding an HLA-A-
B-C, -DR MLC negative donor (7). We understand now better than before
why HLA-DR identical unrelated indi^iduals are so often MLC positive.
This is certainly due to incompatibility for MLC stimulating determi-
Inants other than HLA-DR. Two of these have been identified; products of
the SB (PL3) locus to the left of HÜA-DR and' the LB-Q locus to the righ
Mismatches for these determinants se
transplantation; in bone marrow trar
1 to _be_s|_tudied__._
Leaving matching for the class II ar
feasibility of finding class I ident
em not to be a deterrent in renal
splantation their relevance remains
tigens aside, we have analysed the
ical bone marrow donors in a file
of 10.000. For 28 patients who had no HLA identical sibling donor, we
would have been able to provide for 18 of them 5 to over a 100 unre-
lated class I identical donors. Although the logistics offer thus for
about 2/3 of our patients no unsurmquntable problems the Implementation
of such an Operation will take considerable time. Such protocols should
be reviewed by the medical ethics cdmmittee, informed consent should be
obtained as well as adequate reimbuisement of the costs.
JThe question remains whether HLA idantity is really necessary. The
jhaploidentical grafts which often function so well, testify that this j
Jis not always the case. Recent data in renal allograft studies have |
jprovided us with data which are relevant in this respect. [
They showed that some AB and DR misriiatched renal grafts did extremely j
well. It was assutned that this was cjue to a low responder characteristiij;
'of the recipient, at least as far as HLA allo-antigens were concerned. j
ι The first significant evidence that immune response genes might be in- )
volved in developing immunity against non-HLA antigens was unearthened ]
ιby Baldwin et al. when they showed ifhat only HLA-DRw6 positive indivi- j
duals formed antibodies against antigens present on some endothelial
cells and monocytes (8). HLA~DRw6 appeared to act as an immune response
,(Ir) gene for these EM antigens.
'This study was undermore criticized .because it is notoriously difficult
to type for HLA-DRw6. Recently however the definition of these class II
antigens has been much improved (9)ι and it seemed to be a good moment
•to assess the importance of HLA~DRw6 as Ir gene for HLA alloantigens.
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|Figure 2 shows that overall renal graft survival is poorer in HLA-DRw6
.positive than in negative ones. (10} Α finding which in the meantime
ihas been confirmed by others (P.J. Morris personal communication). In
contrast matching for HLA-DR seems to be very effective in DRw6 posi-
tive and only of borderline importance in DRw6 negative recipients.
,That this was not a red herring is shown in figure 3, which shows the
jinfluence of matching for HLA-DR on renal graft survival in Eurotrans-
iplant (G.F.J. Hendriks personal communication).
IFigure 2.
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Figure 3.
RENAL ALLOGRAFT SURVIVAL WITH RESPECT
TO THE YEAROF TRANSPLANTATION.
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In the years before 1978 typing for ;HLA-DR was possible in Leiden only,
thus donors were typed but not matched with recipients for HLA-DR. In
1980 most centers had implemented HLA-DR typing and matching became
feasible. Over these years graft suuvival at one year post-transplant
in the HLA-DRw6 negative group remained unchanged but in the HLA-DRw6
positive group rose from about 35% to over 70%. This is thus a con-
ifirmation on an independent set of data of the findings shown in
figure 2. Finally it could be shown'that in HLA-DRw6 negative indivi-
|duals pretransplant blood transfusion improved graft survival quite
substantially vhile in DRw6 positive individuals it appeared to have no
•effect. These are thus 3 different dbservations which all suggest that
;DRw6 is a strong Ir gene for incompatible HLA antigens, and that match-
1
 ing for DR (but not pretransplant bl!ood transfusion) turns the DRw6
positive recipient from a high in a low responder.
The Situation appears to be inversed if DRw6 is present in the donor.
In that Situation it appears to act as an activator of suppressor
'cells. In figure 4 it is shown that if a IILA-DRw6 negative recipient
is transplanted with kidney from a donor which is mismatched for one
{HLA-DR antigen, graft survival is excellent (>90%), if that antigen
ί is DRw6 but only average (+ 70%) if -it is any other DR antigen (p =
ί Ι
0.01). Similar findings were observed when the outcome of grafts which
Iwere mismatched for two DR antigens were analysed (Hendriks et al. to
'be submitted). i
In conclusion, it appears that DRw6 in the recipient of a renal allo-
graft acts as a strong Ir gene both for non-HLA and HLA antigens, but
jwhen it is present in the donor it acts as an activator of suppressor
icells. To which extent these data can be extrapolated to the Situation
in bone marrow transplantation remains to be seen. The partly mismatch-
ed family transplants might be bett^r material to study and this the
working party on immunology plans to do.
Figure 4
ORW6-NEG RECIPIENTSOF I-OR-MISM
FIRST RENAL ALLOGRAFTS ( Ν Ί 1 3 )
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Even if such studies would not reveal a relation between HLA-DRw6 and
, the prognosis of partly mismatched bone marrow grafts, the results in
I renal transplantation remain relevant for haematologists. This is so
1 because they provide for the first time an indication that it is
possible to activate the suppressor circuit in man. This is obviously
not only important for the control of the homograft reaction, but also
of the graft versus host reaction and possibly even of autoimmune
disease. J
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